POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Pfizer vaccine candidate more than 90% effective in preventing coronavirus

Christian Fernsby |
Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against coronavirus in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

Article continues below




"The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO.

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.

Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds.

The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed coronavirus cases have accrued.

The study also will evaluate the potential for the vaccine candidate to provide protection against coronavirus in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe coronavirus disease.

In addition to the primary efficacy endpoints evaluating confirmed coronavirus cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well.


What to read next

3-in-1 vaccine against traveler's diarrhea
New Zealand signs first coronavirus vaccine purchase agreement
Candidate Ebola vaccine still effective when highly diluted